title: Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma.
abstract: Hyperthermic Antiblastic Perfusion (HAP) is a widely used method for the treatment of recurrent limb melanoma. In terms of tumor response, locoregional control and survival HAP has led to better results than those achieved with any other treatment. The aim of this report is to analyze our own experience with HAP in locally advanced limb melanoma. Thirty-two patients were submitted to HAP. HAP lasted 60 minutes, with maximal local temperature of 40.5-42 degrees C using melphalan 10 mg/L limb volume as antiblastic agent. Twenty patients had in-transit metastases and 12 local recurrence. Regional nodes were involved in 12 patients. Systemic leakage monitored with 125I or 99Tc ranged between 5-30% (mean 14%). No operative mortality nor major complications occurred. Local toxicity scored Wieberdink grade I in 8 patients, grade II in 17, grade III in 6 and grade IV in 1 case. Response rate (UICC) in the 16 patients treated with unexcised lesions was 94% (56% complete responses). With a median follow-up of 29 months (2-126) 14 patients relapsed after a median time of 10 months, and 17 patients are currently disease free, 3 of these are being reexcised and 3 re-perfused. Actuarial 5 years survival was 64%, with 39% disease free to the first relapse. Our results are consistent with the literature indicating HAP as a safe procedure with a high evidence of clinical responses.
authors.affiliation: Department of Clinical Surgery, University of Genoa, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Decian
authors.forename: G
authors.initials: G
authors.lastname: Mondini
authors.forename: R
authors.initials: R
authors.lastname: Demarchi
authors.forename: G
authors.initials: G
authors.lastname: Muzio
authors.forename: A
authors.initials: A
authors.lastname: Sementa
authors.forename: M M
authors.initials: MM
authors.lastname: Bocchio
authors.forename: C
authors.initials: C
authors.lastname: Spirito
authors.forename: G
authors.initials: G
authors.lastname: Simoni
authors.forename: D
authors.initials: D
authors.lastname: Civalleri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D007866:Leg; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan